ATOS
Price
$0.84
Change
-$0.03 (-3.45%)
Updated
May 23, 01:47 PM (EDT)
Capitalization
112.36M
87 days until earnings call
PDSB
Price
$1.64
Change
+$0.06 (+3.82%)
Updated
May 23, 02:44 PM (EDT)
Capitalization
71.76M
82 days until earnings call
Interact to see
Advertisement

ATOS vs PDSB

Header iconATOS vs PDSB Comparison
Open Charts ATOS vs PDSBBanner chart's image
Atossa Therapeutics
Price$0.84
Change-$0.03 (-3.45%)
Volume$200
Capitalization112.36M
PDS Biotechnology
Price$1.64
Change+$0.06 (+3.82%)
Volume$669
Capitalization71.76M
ATOS vs PDSB Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. PDSB commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and PDSB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (ATOS: $0.87 vs. PDSB: $1.57)
Brand notoriety: ATOS and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 88% vs. PDSB: 960%
Market capitalization -- ATOS: $112.36M vs. PDSB: $71.76M
ATOS [@Biotechnology] is valued at $112.36M. PDSB’s [@Biotechnology] market capitalization is $71.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATOS and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 5 TA indicator(s) are bullish while PDSB’s TA Score has 6 bullish TA indicator(s).

  • ATOS’s TA Score: 5 bullish, 5 bearish.
  • PDSB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than ATOS.

Price Growth

ATOS (@Biotechnology) experienced а -11.74% price change this week, while PDSB (@Biotechnology) price change was +16.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.70%. For the same industry, the average monthly price growth was +2.74%, and the average quarterly price growth was -2.88%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($112M) has a higher market cap than PDSB($71.8M). PDSB YTD gains are higher at: -3.681 vs. ATOS (-7.859). ATOS has higher annual earnings (EBITDA): -29.46M vs. PDSB (-36.65M). ATOS has more cash in the bank: 74.8M vs. PDSB (49.8M). ATOS has less debt than PDSB: ATOS (0) vs PDSB (24.7M). ATOS (0) and PDSB (0) have equivalent revenues.
ATOSPDSBATOS / PDSB
Capitalization112M71.8M156%
EBITDA-29.46M-36.65M80%
Gain YTD-7.859-3.681214%
P/E RatioN/AN/A-
Revenue00-
Total Cash74.8M49.8M150%
Total Debt024.7M-
FUNDAMENTALS RATINGS
ATOS vs PDSB: Fundamental Ratings
ATOS
PDSB
OUTLOOK RATING
1..100
618
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
41
Fair valued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9297
PRICE GROWTH RATING
1..100
4844
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (29) in the Medical Specialties industry is in the same range as PDSB (41) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's Profit vs Risk Rating (94) in the Pharmaceuticals Major industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that PDSB’s stock grew similarly to ATOS’s over the last 12 months.

ATOS's SMR Rating (92) in the Medical Specialties industry is in the same range as PDSB (97) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as ATOS (48) in the Medical Specialties industry. This means that PDSB’s stock grew similarly to ATOS’s over the last 12 months.

PDSB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that PDSB’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSPDSB
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BDORY4.510.04
+1.01%
Banco Do Brasil SA
BYDDF58.89-0.21
-0.36%
BYD Co., Ltd.
TCCPY5.57-0.03
-0.54%
Technopro Holdings Inc.
IVPAF9.41-0.11
-1.19%
Ivanhoe Mines Ltd.
NGPHF0.07N/A
-2.97%
Northern Graphite Corp.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-0.09%
ABOS - ATOS
52%
Loosely correlated
N/A
GBIO - ATOS
48%
Loosely correlated
-3.38%
PDSB - ATOS
46%
Loosely correlated
-0.63%
NTLA - ATOS
46%
Loosely correlated
+2.83%
ABCL - ATOS
46%
Loosely correlated
N/A
More